For over three decades, CEI has advocated health care reforms that put more power in the hands of consumers to choose their health providers, treatment protocols, and scope of insurance coverage. We have advocated reform of the Food and Drug Administration’s drug and device approval process to allow for greater flexibility and patient choice. And in 2013, CEI organized the court challenges to Obamacare’s exchange subsidies that concluded with the Supreme Court’s King v. Burwell decision.
Healthcare Issue Areas
Featured Posts
Blog
The TrumpRx medicine will prove worse than the disease
On September 30, President Trump, standing alongside the CEO of Pfizer, announced a multifaceted deal wherein Pfizer would inoculate itself from new regulations and…
Blog
Free the Economy podcast: Obamacare problems with Jeremy Nighohossian
In this week’s episode we talk about the unintended consequences of the Sarbanes-Oxley Act of 2002, decarbonization of economic growth, and resources…
Blog
The problem with Obamacare is Obamacare
This year, the COVID-induced expansion of the Affordable Care Act (ACA) will expire. Extending the expanded subsidies has become a point of contention between Republicans…
Search Posts
Blog
The numbers don’t add up in new Medicaid paper
In a recently released working paper, authors Angela Wyse and Bruce D. Meyer purport to show that the ACA Medicaid expansion saved 27,400 lives…
Letters
CEI joins ATR Coalition Urging CRA on Medical Debt Rule
Dear Member of Congress, We are writing to express our concerns regarding the Consumer Financial Protection Bureau’s finalized rule on eliminating medical debt records from…
Blog
FTC’s second interim report on PBMs: Don’t hold your breath
The Federal Trade Commission (FTC) will consider issuing a second interim report on Pharmacy Benefit Managers (PBMs) tomorrow during its January 14 open meeting.
Blog
Congress shouldn’t rely on incomplete FTC PBM study
Lawmakers are making a last-minute push to regulate the practices of pharmacy benefit managers (PBMs) during the lame duck session. However, it would be a…
Wall Street Journal
A Thumb on the Scale for Wegovy
The Biden administration announced one more bit of executive overreach on its way out the door. On Nov. 26, the Centers for Medicare and Medicaid…
National Review
Telehealth Is Less Promising Than It First Seemed
A key issue facing Congress in its postelection, “lame duck” session is whether to extend regulatory flexibilities expiring at year end that make telehealth services more…